How I manage iron overload in the hematopoietic cell transplantation setting

2.

Hentze

MW

,

Muckenthaler

MU

,

Galy

B

,

Camaschella

C

.

Two to tango: regulation of mammalian iron metabolism

.

Cell

.

2010

;

142

(

1

):

24

-

38

.

3.

Pilo

F

,

Cilloni

D

,

Della Porta

MG

, et al.

Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: it's more a matter of burden or more of exposure to toxic iron form?

.

Leuk Res

.

2022

;

114

:

106792

.

4.

Rishi

G

,

Wallace

DF

,

Subramaniam

VN

.

Hepcidin: regulation of the master iron regulator

.

Biosic Rep

.

2015

;

35

(

3

):

e00192

.

5.

Wang

C-Y

,

Babitt

JL

.

Hepcidin regulation in the anemia of inflammation

.

Curr Opin Hematol

.

2016

;

23

(

3

):

189

-

197

.

6.

Weiss

G

,

Goodnough

LT

.

Anemia of chronic disease

.

N Engl J Med

.

2005

;

352

:

1011

-

1023

.

7.

Papanikolaou

G

,

Pantopoulos

K

.

Systemic iron homeostasis and erythropoiesis

.

IUBMB Life

.

2017

;

69

(

6

):

399

-

413

.

8.

Cabantchik

ZI

.

Labile iron in cells and body fluids: physiology, pathology, and pharmacology

.

Front Pharmacol

.

2014

;

5

:

45

.

9.

de Swart

L

,

Hendriks

JCM

,

van der Vorm

LN

, et al.

Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders

.

Haematologica

.

2016

;

101

(

1

):

38

-

45

.

10.

Dürken

M

,

Nielsen

P

,

Knobel

S

, et al.

Nontransferrin-bound iron in serum of patients receiving bone marrow transplants

.

Free Radic Biol Med

.

1997

;

22

(

7

):

1159

-

1163

.

11.

Hirschhorn

T

,

Stockwell

BR

.

The development of the concept of ferroptosis

.

Free Radic Biol Med

.

2019

;

133

:

130

-

143

.

12.

Galadari

S

,

Rahman

A

,

Pallichankandy

S

,

Thayyullathil

F

.

Reactive oxygen species and cancer paradox: to promote or to suppress?

.

Free Radic Biol Med

.

2017

;

104

:

144

-

164

.

13.

Cabantchik

IZ

,

Hershko

C

.

Plasma nontransferrin bound iron-nontransferrin bound iron revisited: Implications for systemic iron overload and in iv iron supplementation

.

Am J Hematol

.

2022

;

97

(

1

):

7

-

9

.

14.

Pilo

F

,

Angelucci

E

.

Iron toxicity and hemopoietic cell transplantation: time to change the paradigm

.

Mediterr J Hematol Infect Dis

.

2019

;

11

(

1

):

e2019030

.

15.

Coates

TD

.

Physiology and pathophysiology of iron in hemoglobin-associated diseases

.

Free Radic Biol Med

.

2014

;

72

:

23

-

40

.

16.

Pilo

F

,

Angelucci

E

.

A storm in the niche: iron, oxidative stress and haemopoiesis

.

Blood Rev

.

2018

;

32

(

1

):

29

-

35

.

17.

Ganz

T

,

Nemeth

E

.

Hepcidin and iron homeostasis

.

Biochim Biophys Acta

.

2012

;

1823

(

9

):

1434

-

1443

.

18.

Coates

TD

.

Iron overload in transfusion-dependent patients

.

Hematology Am Soc Hematol Educ Program

.

2019

;

2019

(

1

):

337

-

344

.

19.

Lucarelli

G

,

Galimberti

M

,

Polchi

P

, et al.

Marrow transplantation in patients with advanced thalassemia

.

N Engl J Med

.

1987

;

316

(

17

):

1050

-

1055

.

20.

Lucarelli

G

,

Polchi

P

,

Galimberti

M

, et al.

Marrow transplantation for thalassaemia following busulphan and cyclophosphamide

.

Lancet

.

1985

;

1

(

8442

):

1355

-

1357

.

21.

Lucarelli

G

,

Galimberti

M

,

Polchi

P

, et al.

Bone marrow transplantation in patients with thalassemia

.

N Engl J Med

.

1990

;

322

(

7

):

417

-

421

.

22.

Armand

P

,

Kim

HT

,

Rhodes

J

, et al.

Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation

.

Biol Blood Marrow Transplant

.

2011

;

17

(

6

):

852

-

860

.

23.

Rose

C

,

Ernst

O

,

Hecquet

B

, et al.

Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT)

.

Haematologica

.

2007

;

92

(

6

):

850

-

853

.

24.

Pan

T

,

Ji

Y

,

Liu

H

, et al.

Impact of iron overload and iron chelation with deferasirox on outcomes of patients with severe aplastic anemia after allogeneic hematopoietic stem cell transplantation

.

Transplant Cell Ther

.

2023

;

29

(

8

):

507.e1

-

507.e8

.

25.

Leitch

HA

,

Fibach

E

,

Rachmilewitz

E

.

Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies

.

Crit Rev Oncol Hematol

.

2017

;

113

:

156

-

170

.

26.

Yan

Z

,

Chen

X

,

Wang

H

, et al.

Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis

.

Medicine (Baltimore)

.

2018

;

97

(

27

):

e10310

.

27.

Naoum

FA

,

Espósito

BP

,

Zotarelli Filho

IJ

.

Impact of labile plasma iron and iron chelation on the viability of cultured mononuclear cells from patients undergoing autologous hematopoietic stem cell transplantation

.

Blood Res

.

2017

;

52

(

2

):

135

-

136

.

28.

Brittenham

GM

. Disorders of iron metabolism: iron deficiency and overload. In:

Hoffman

R

,

Benz

E

,

Shattil

S

, eds.

Hematology basic principles and practice

.

Philadelphia

:

Elsevier

;

2005

:

481

-

497

.

29.

Platzbecker

U

,

Ehninger

G

,

Bornhäuser

M

.

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation

.

Blood

.

2007

;

110

(

8

):

3083

-

3084

.

30.

Trottier

BJ

,

Burns

LJ

,

DeFor

TE

,

Cooley

S

,

Majhail

NS

.

Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content

.

Blood

.

2013

;

122

(

9

):

1678

-

1684

.

31.

Wermke

M

,

Schmidt

A

,

Middeke

JM

, et al.

MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation

.

Clin Cancer Res

.

2012

;

18

(

23

):

6460

-

6468

.

32.

Alessandrino

EP

,

Della Porta

MG

,

Bacigalupo

A

, et al.

Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study

.

Haematologica

.

2010

;

95

(

3

):

476

-

484

.

33.

Alousi

AM

,

Saliba

RM

.

Pre-transplant transfusion burden and transplant outcomes, is there a case for earlier transplant?

.

Transplant Cell Ther

.

2021

;

27

(

8

):

625

-

626

.

34.

Gattermann

N

,

Rachmilewitz

EA

.

Iron overload in MDS-pathophysiology, diagnosis, and complications

.

Ann Hematol

.

2011

;

90

(

1

):

1

-

10

.

35.

Noetzli

LJ

,

Mittelman

SD

,

Watanabe

RM

,

Coates

TD

,

Wood

JC

.

Pancreatic iron and glucose dysregulation in thalassemia major

.

Am J Hematol

.

2012

;

87

(

2

):

155

-

160

.

36.

Noetzli

LJ

,

Papudesi

J

,

Coates

TD

,

Wood

JC

.

Pancreatic iron loading predicts cardiac iron loading in thalassemia major

.

Blood

.

2009

;

114

(

19

):

4021

-

4026

.

37.

Pinto

VM

,

Bacigalupo

L

,

Gianesin

B

, et al.

Lack of correlation between heart, liver and pancreas MRI-R2∗: Results from long-term follow-up in a cohort of adult β-thalassemia major patients

.

Am J Hematol

.

2018

;

93

(

3

):

E79

-

E82

.

38.

Angelucci

E

,

Pilo

F

,

Coates

TD

.

Transplantation in thalassemia: revisiting the pesaro risk factors 25 years later

.

Am J Hematol

.

2017

;

92

(

5

):

411

-

413

.

39.

Cappellini

MD

,

Farmakis

D

,

Porter

J

,

Taher

A

.

Guidelines for the management of transfusion dependent thalassaemia (TDT)

.

Thalassaemia International Federation

;

2014

.

40.

Wermke

M

,

Eckoldt

J

,

Götze

KS

, et al.

Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial

.

Lancet Haematol

.

2018

;

5

(

5

):

e201

-

e210

.

41.

Angelucci

E

,

Brittenham

GM

,

McLaren

CE

, et al.

Hepatic iron concentration and total body iron stores in thalassemia major

.

N Engl J Med

.

2000

;

343

(

5

):

327

-

331

.

42.

Angelucci

E

,

Baronciani

D

,

Lucarelli

G

, et al.

Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies

.

Br J Haematol

.

1995

;

89

(

4

):

757

-

761

.

43.

Wood

JC

,

Enriquez

C

,

Ghugre

N

, et al.

MRI R2 and R2∗ mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients

.

Blood

.

2005

;

106

(

4

):

1460

-

1465

.

44.

St Pierre

TG

,

Clark

PR

,

Chua-anusorn

W

, et al.

Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance

.

Blood

.

2005

;

105

(

2

):

855

-

861

.

45.

Ludin

A

,

Gur-Cohen

S

,

Golan

K

, et al.

Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment

.

Antioxid Redox Signal

.

2014

;

21

(

11

):

1605

-

1619

.

46.

Bigarella

CL

,

Liang

R

,

Ghaffari

S

.

Stem cells and the impact of ROS signaling

.

Development

.

2014

;

141

(

22

):

4206

-

4218

.

47.

Ye

Z-W

,

Zhang

J

,

Townsend

DM

,

Tew

KD

.

Oxidative stress, redox regulation and diseases of cellular differentiation

.

Biochim Biophys Acta

.

2015

;

1850

(

8

):

1607

-

1621

.

48.

Balogh

E

,

Tolnai

E

,

Nagy

B

, et al.

Iron overload inhibits osteogenic commitment and differentiation of mesenchymal stem cells via the induction of ferritin

.

Biochim Biophys Acta

.

2016

;

1862

(

9

):

1640

-

1649

.

49.

Borriello

A

,

Caldarelli

I

,

Speranza

MC

, et al.

Iron overload enhances human mesenchymal stromal cell growth and hampers matrix calcification

.

Biochim Biophys Acta

.

2016

;

1860

(

6

):

1211

-

1223

.

50.

Bulycheva

E

,

Rauner

M

,

Medyouf

H

, et al.

Myelodysplasia is in the niche: novel concepts and emerging therapies

.

Leukemia

.

2015

;

29

(

2

):

259

-

268

.

51.

Muretto

P

,

Del Fiasco

S

,

Angelucci

E

,

De Rosa

F

,

Lucarelli

G

.

Bone marrow transplantation in thalassemia: modifications of hepatic iron overload and associated lesions after long-term engrafting

.

Liver

.

1994

;

14

(

1

):

14

-

24

.

52.

Naoum

FA

,

Espósito

BP

,

Ruiz

LP

, et al.

Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation

.

Acta Haematol

.

2014

;

131

(

4

):

222

-

226

.

53.

Duca

L

,

Cappellini

MD

,

Baronciani

D

, et al.

Non-transferrin-bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload

.

Am J Hematol

.

2018

;

93

(

9

):

E250

-

E252

.

54.

Chai

X

,

Li

D

,

Cao

X

, et al.

ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice

.

Sci Rep

.

2015

;

5

(

1

):

10181

.

55.

Okabe

H

,

Suzuki

T

,

Uehara

E

,

Ueda

M

,

Nagai

T

,

Ozawa

K

.

The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice

.

Eur J Haematol

.

2014

;

93

(

2

):

118

-

128

.

56.

Hilken

A

,

Langebrake

C

,

Wolschke

C

, et al.

Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT)

.

Ann Hematol

.

2017

;

96

(

8

):

1379

-

1388

.

57.

Naoum

FA

,

Espósito

BP

,

Cançado

RD

.

Impact of conditioning and engraftment on iron status in hematopoietic stem cell transplantation: Contribution of labile plasma iron

.

Hematol Oncol Stem Cell Ther

.

2016

;

9

(

4

):

165

-

167

.

58.

Yegin

ZA

,

Paşaoğlu

H

,

Aki

SZ

, et al.

Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic stem cell transplantation

.

Int J Lab Hematol

.

2011

;

33

(

4

):

414

-

423

.

59.

Baronciani

D

,

Angelucci

E

,

Potschger

U

, et al.

Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010

.

Bone Marrow Transplant

.

2016

;

51

(

4

):

536

-

541

.

60.

Angelucci

E

,

Matthes-Martin

S

,

Baronciani

D

, et al.

Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel

.

Haematologica

.

2014

;

99

(

5

):

811

-

820

.

61.

Kirk

P

,

Roughton

M

,

Porter

JB

, et al.

Cardiac T2∗ magnetic resonance for prediction of cardiac complications in thalassemia major

.

Circulation

.

2009

;

120

(

20

):

1961

-

1968

.

62.

Pennell

DJ

,

Udelson

JE

,

Arai

AE

, et al.

Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association

.

Circulation

.

2013

;

128

(

3

):

281

-

308

.

63.

Tanner

MA

,

Galanello

R

,

Dessi

C

, et al.

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

.

Circulation

.

2007

;

115

(

14

):

1876

-

1884

.

64.

Peffault de Latour

R

,

Kulasekararaj

A

,

Iacobelli

S

, et al.

Eltrombopag added to immunosuppression in severe aplastic anemia

.

N Engl J Med

.

2022

;

386

(

1

):

11

-

23

.

65.

Voso

MT

,

Leone

G

,

Piciocchi

A

, et al.

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study

.

Ann Oncol

.

2017

;

28

(

7

):

1547

-

1553

.

66.

Kröger

N

,

Sockel

K

,

Wolschke

C

, et al.

Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)

.

J Clin Oncol

.

2021

;

39

(

30

):

3318

-

3327

.

67.

Koenecke

C

,

Göhring

G

,

de Wreede

LC

, et al.

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation

.

Haematologica

.

2015

;

100

(

3

):

400

-

408

.

68.

Gagelmann

N

,

Eikema

D-J

,

Stelljes

M

, et al.

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

.

Haematologica

.

2019

;

104

(

5

):

929

-

936

.

69.

Gaziev

D

,

Giardini

C

,

Angelucci

E

, et al.

Intravenous chelation therapy during transplantation for thalassemia

.

Haematologica

.

1995

;

80

(

4

):

300

-

304

.

70.

Essmann

S

,

Heestermans

M

,

Dadkhah

A

, et al.

Iron chelation with deferasirox suppresses the appearance of labile plasma iron during conditioning chemotherapy prior to allogeneic stem cell transplantation

.

Transplant Cell Ther

.

2023

;

29

(

1

):

42.e1

-

42.e6

.

71.

Fritsch

A

,

Langebrake

C

,

Nielsen

P

, et al.

Deferasirox (Exjade®) given during conditioning regimen (FLAMSA/Busulfan/ATG) reduces the appearance of labile plasma iron in patients undergoing allogeneic stem cell transplantation [abstract]

.

Blood

.

2011

;

118

(

21

):

3023

.

72.

Essmann

S

,

Dadkhah

A

,

Janson

D

, et al.

Iron chelation with deferasirox increases busulfan AUC during conditioning chemotherapy prior to allogeneic stem cell transplantation

.

Transplant Cell Ther

.

2022

;

28

(

2

):

115.e1

-

115.e5

.

73.

Kremastinos

DT

,

Farmakis

D

.

Iron overload cardiomyopathy in clinical practice

.

Circulation

.

2011

;

124

(

20

):

2253

-

2263

.

74.

Nomani

H

,

Bayat

G

,

Sahebkar

A

, et al.

Atrial fibrillation in β-thalassemia patients with a focus on the role of iron-overload and oxidative stress: a review

.

J Cell Physiol

.

2019

;

234

(

8

):

12249

-

12266

.

75.

Glickstein

H

,

El

RB

,

Link

G

, et al.

Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences

.

Blood

.

2006

;

108

(

9

):

3195

-

3203

.

76.

Porter

JB

,

Rafique

R

,

Srichairatanakool

S

, et al.

Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use

.

Ann N Y Acad Sci

.

2005

;

1054

(

1

):

155

-

168

.

77.

Porter

JB

,

Abeysinghe

RD

,

Marshall

L

,

Hider

RC

.

Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy

.

Blood

.

1996

;

88

(

2

):

705

-

713

.

78.

Chang

H-H

,

Lu

M-Y

,

Liao

Y-M

, et al.

Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia

.

Pediatr Blood Cancer

.

2011

;

56

(

3

):

420

-

424

.

79.

Visani

G

,

Guiducci

B

,

Giardini

C

,

Loscocco

F

,

Ricciardi

T

,

Isidori

A

.

Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT

.

Bone Marrow Transplant

.

2014

;

49

(

4

):

585

-

587

.

80.

Olivieri

J

,

Mancini

G

,

Goteri

G

, et al.

Reversal of poor graft function with iron-chelating therapy after allogeneic transplantation for severe aplastic anemia

.

Leuk Lymphoma

.

2016

;

57

(

4

):

965

-

968

.

81.

Forni

GL

,

Podestà

M

,

Musso

M

, et al.

Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major

.

Haematologica

.

2013

;

98

(

4

):

555

-

559

.

82.

Kamble

RT

,

Selby

GB

,

Mims

M

,

Kharfan-Dabaja

MA

,

Ozer

H

,

George

JN

.

Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

.

Biol Blood Marrow Transplant

.

2006

;

12

(

5

):

506

-

510

.

83.

Deeg

HJ

,

Spaulding

E

,

Shulman

HM

.

Iron overload, hematopoietic cell transplantation, and graft-versus-host disease

.

Leuk Lymphoma

.

2009

;

50

(

10

):

1566

-

1572

.

84.

Angelucci

E

,

Muretto

P

,

Lucarelli

G

, et al.

Treatment of iron overload in the “ex-thalassemic.” report from the phlebotomy program

.

Ann N Y Acad Sci

.

1998

;

850

(

1

):

288

-

293

.

85.

O'Connell

MJ

,

Peters

TJ

.

Ferritin and haemosiderin in free radical generation, lipid peroxidation and protein damage

.

Chem Phys Lipids

.

1987

;

45

(

2-4

):

241

-

249

.

86.

Ward

RJ

,

Legssyer

R

,

Henry

C

,

Crichton

RR

.

Does the haemosiderin iron core determine its potential for chelation and the development of iron-induced tissue damage?

.

J Inorg Biochem

.

2000

;

79

(

1-4

):

311

-

317

.

87.

Angelucci

E

,

Muretto

P

,

Nicolucci

A

, et al.

Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation

.

Blood

.

2002

;

100

(

1

):

17

-

21

.

88.

Loréal

O

,

Deugnier

Y

,

Moirand

R

, et al.

Liver fibrosis in genetic hemochromatosis. respective roles of iron and non-iron-related factors in 127 homozygous patients

.

J Hepatol

.

1992

;

16

(

1-2

):

122

-

127

.

89.

Mariotti

E

,

Angelucci

E

,

Agostini

A

,

Baronciani

D

,

Sgarbi

E

,

Lucarelli

G

.

Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden

.

Br J Haematol

.

1998

;

103

(

4

):

916

-

921

.

90.

Muretto

P

,

Angelucci

E

,

Lucarelli

G

.

Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation

.

Ann Intern Med

.

2002

;

136

(

9

):

667

-

672

.

91.

Angelucci

E

,

Muretto

P

,

Lucarelli

G

, et al.

Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for phlebotomy treatment of transplanted thalassemia patients

.

Blood

.

1997

;

90

(

3

):

994

-

998

.

92.

Inati

A

,

Kahale

M

,

Sbeiti

N

, et al.

One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation

.

Pediatr Blood Cancer

.

2017

;

64

(

1

):

188

-

196

.

93.

Coates

TD

,

Carson

S

,

Wood

JC

,

Berdoukas

V

.

Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?

.

Ann N Y Acad Sci

.

2016

;

1368

(

1

):

95

-

106

.

94.

Puliyel

M

,

Mainous

AG

,

Berdoukas

V

,

Coates

TD

.

Iron toxicity and its possible association with treatment of cancer: lessons from hemoglobinopathies and rare, transfusion-dependent anemias

.

Free Radic Biol Med

.

2015

;

79

:

343

-

351

.

95.

Ellervik

C

,

Tybjærg-Hansen

A

,

Nordestgaard

BG

.

Total mortality by transferrin saturation levels: two general population studies and a metaanalysis

.

Clin Chem

.

2011

;

57

(

3

):

459

-

466

.

96.

Frangoul

H

,

Altshuler

D

,

Cappellini

MD

, et al.

CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia

.

N Engl J Med

.

2021

;

384

(

3

):

252

-

260

.

97.

Locatelli

F

,

Thompson

AA

,

Kwiatkowski

JL

, et al.

Betibeglogene autotemcel gene therapy for non-β0/β0 genotype β-thalassemia

.

N Engl J Med

.

2022

;

386

(

5

):

415

-

427

.

98.

Baronciani

D

,

Casale

M

,

De Franceschi

L

,

Graziadei

G

.

Selecting ß-thalassemia patients for gene therapy: a decision-making algorithm

.

Hemasphere

.

2021

;

5

(

5

):

e555

.